UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
Interleukin Genetics, Inc.
____________________________________________________________
(Name of Issuer)
Common Stock, $.001 par value per share
____________________________________________________________
(Title of Class of Securities)
458738101
______________________________________
(CUSIP Number)
December 31, 2007
_____________________________________________________________
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Exchange Act
or otherwise subject to the liabilities of that section of the Exchange Act
but shall be subject to all other provisions of the Exchange Act (however,
see the Notes).
SCHEDULE 13G/A
---------------------------------------------------------------------------
CUSIP No.: 458738101
---------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
Jeffrey K. Peterson
---------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [__]
---------------------------------------------------------------------------
3 SEC USE ONLY
---------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
---------------------------------------------------------------------------
5 SOLE VOTING POWER
2,374,237
NUMBER OF SHARES -------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 0
EACH -------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 2,374,237
WITH -------------------------------------------
8 SHARED DISPOSITIVE POWER
0
---------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,374,237
---------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES [ ]
---------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.7%
---------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
IN
---------------------------------------------------------------------------
2
SCHEDULE 13G/A
---------------------------------------------------------------------------
CUSIP No.: 458738101
Item 1.
(a) Name of Issuer:
Interleukin Genetics, Inc.
(b) Address of Issuer's Principal Executive Offices:
135 Beaver Street
Waltham, MA 02452
Item 2.
(a) Name of Person Filing:
Jeffrey K. Peterson
(b) Address of Principal Business Office or, if none, Residence:
1707 Waldemere Street
Sarasota, FL 34239
(c) Citizenship:
United States Citizen
(d) Title of Class of Securities:
Common Stock, $.001 par value per share (the
"Common Stock")
(e) CUSIP Number:
458738101
Item 3.
If this statement is filed pursuant to Sections 240.13d-1(b) or
240.13d-2(b)or (c), check whether the person filing is a:
Not applicable
3
SCHEDULE 13G/A
----------------------------------------------------------------------------
CUSIP No.: 458738101
Item 4. Ownership.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
As of December 31, 2007: Mr. Peterson was the beneficial
owner of 2,374,237 shares of the issuer's Common Stock.
(b) Percent of class:
As of December 31, 2007: The 2,374,237 shares owned by
Mr. Peterson constituted 7.7% of the shares outstanding.
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Mr. Peterson has the sole power to vote or direct
the vote as to the 2,374,237 shares owned by him.
(ii) Shared power to vote or to direct the vote: N/A
(iii) Sole power to dispose or to direct the disposition of:
Mr. Peterson has the sole power to dispose or to direct
the disposition of the 2,374,237 shares owned by him.
(iv) Shared power to dispose or to direct the disposition
of: N/A
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner of more
than five percent of the class of securities check the following [ ].
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
4
SCHEDULE 13G/A
------------------------------------------------------------------------------
CUSIP No.: 458738101
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not Applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.
Not applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
Dated: January 15, 2008
/s/ Jeffrey K. Peterson
__________________________________
Jeffrey K. Peterson
5